Abstract：
Intravitreal injection (IVI) of a drug allows for immediate intraocular concentrations of active ingredients higher than those obtained by intravenous injection while reducing the risk of systemic side effects. Today, IVI\'s play a central role in the treatment of many vitreoretinal diseases. With the aging of the population and the advent of vascular endothelial growth factor (VEGF) antagonists, their indications have increased exponentially, creating structural, organizational and economic difficulties. IVI is now one of the most widely performed medical procedures in industrialized countries, and its indications are expected to expand further in the near future with the development of new molecules. Although the overall safety of this practice is proven, an IVI exposes the patient to a 0.05 % risk of endophthalmitis, the consequences of which are often dramatic. This article details the current recommendations, in particular regarding asepsis and antisepsis, and proposes a typical sequence for performing an IVI.
摘要：
药物的玻璃体内注射(IVI)允许活性成分的即时眼内浓度高于通过静脉内注射获得的浓度,同时降低全身副作用的风险。今天,IVI在许多玻璃体视网膜疾病的治疗中起着核心作用。随着人口老龄化和血管内皮生长因子（VEGF）拮抗剂的出现，他们的适应症呈指数增长，创建结构，组织和经济困难。IVI现在是工业化国家中最广泛使用的医疗程序之一，随着新分子的发展，其适应症有望在不久的将来进一步扩大。尽管这种做法的整体安全性得到了证明，IVI使患者面临0.05％的眼内炎风险，其后果往往是戏剧性的。本文详细介绍了当前的建议，特别是关于无菌和防腐，并提出了执行IVI的典型序列。
